Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review

Georgiadis, Georgios; Zisis, Ioannis-Erineos; Docea, Anca Oana; Tsarouhas, Konstantinos; Fragkiadoulaki, Irene; Mavridis, Charalampos; Karavitakis, Markos; Stratakis, Stavros; Stylianou, Kostas; Tsitsimpikou, Christina; Calina, Daniela; Sofikitis, Nikolaos; Tsatsakis, Aristidis; Mamoulakis, Charalampos

doi:10.3390/jcm9051284

Cited by 35 publications

(36 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other agents such as cardiotrophin-1 and antithrombin III, [ 53 , 54 ] exendin-4, [ 55 ] β-receptor antagonist, [ 56 , 57 ] phosphodiesterase-5 inhibitor, [ 58 – 61 ] an mTOR inhibitor, [ 62 ] exogenous sphingosylphosphorylcholine, [ 63 ] and sodium bicarbonate; [ 64 ] have been investigated in CIN models (Table 4 and Fig. 3 ).…”

Section: Interventions Targeting Ros For Cin Prevention: Evidence Fromentioning

confidence: 99%

Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches

Kusirisin

Chattipakorn

2020

J Transl Med

View full text Add to dashboard Cite

Contrast-induced nephropathy (CIN) or contrast-induced acute kidney injury (CI-AKI) is an iatrogenic acute kidney injury observed after intravascular administration of contrast media for intravascular diagnostic procedures or therapeutic angiographic intervention. High risk patients including those with chronic kidney disease (CKD), diabetes mellitus with impaired renal function, congestive heart failure, intraarterial intervention, higher volume of contrast, volume depletion, old age, multiple myeloma, hypertension, and hyperuricemia had increased prevalence of CIN. Although CIN is reversible by itself, some patients suffer this condition without renal recovery leading to CKD or even end-stage renal disease which required long term renal replacement therapy. In addition, both CIN and CKD have been associated with increasing of mortality. Three pathophysiological mechanisms have been proposed including direct tubular toxicity, intrarenal vasoconstriction, and excessive production of reactive oxygen species (ROS), all of which lead to impaired renal function. Reports from basic and clinical studies showing potential preventive strategies for CIN pathophysiology including low- or iso-osmolar contrast media are summarized and discussed. In addition, reports on pharmacological interventions to reduce ROS and attenuate CIN are summarized, highlighting potential for use in clinical practice. Understanding this contributory mechanism could pave ways to improve therapeutic strategies in combating CIN.

show abstract

Section: Interventions Targeting Ros For Cin Prevention: Evidence Fromentioning

confidence: 99%

Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches

Kusirisin

Chattipakorn

2020

J Transl Med

View full text Add to dashboard Cite

show abstract

“…The reduction of nephrotoxic exposure is one of the effective tools already used in oncological patients [ 30 ]. The animal models suggest the possibility to prevent AKI with the use of phosphodiesterase-5 inhibitors prior to potentially nephrotoxic treatment [ 31 , 32 ]. Independent of the chosen strategy, the threat of renal injury should urge careful follow-up of the patient in order to avoid additional insults triggering irreversible damage to the kidney.…”

Section: Discussionmentioning

confidence: 99%

Clusterin as a New Marker of Kidney Injury in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation—A Pilot Study

Musiał

Augustynowicz

Miśkiewicz-Migoń

et al. 2020

JCM

View full text Add to dashboard Cite

Background and aims: The markers of renal damage defining subclinical AKI are not widely used in children undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). The aim of the study was to evaluate serum and urinary clusterin as indices of kidney injury after alloHSCT in relation to damage (kidney injury molecule (KIM)-1) and functional (cystatin C) markers. Material and methods: Serum and urinary clusterin, KIM-1 and cystatin C concentrations were assessed by ELISA in 27 children before alloHSCT, 24 h, 1, 2, 3 and 4 weeks after alloHSCT and in controls. Results: All parameters were significantly higher in HSCT patients compared to controls even before the transplantation. The serum concentrations increased after HSCT and this rising trend was kept until the third (clusterin) or 4th (KIM-1, cystatin C) week. Urinary clusterin and KIM-1 were elevated until the third week and then decreased yet remained higher than before HSCT. Urinary cystatin C has risen from the second week after HSCT and decreased after the third week but was still higher than before alloHSCT. Conclusions: The features of kidney injury are present even before alloHSCT. Clusterin seems useful in the assessment of subclinical AKI and may become a new early marker of sublethal kidney injury in children.

show abstract

“…Sildenafil is an orally administered phosphodiesterase type 5 (PDE5) inhibitor that permits corpus cavernosum smooth muscle to relax and potentiating erections during sexual stimulation (Langtry and Markham, 1999;Georgiadis et al, 2020;Iordache et al, 2020a). It is also reported that the sildenafil can inhibit the breakdown of cyclic guanosine monophosphate (cGMP) through binding at the phosphodiesterase binding site (Iordache et al, 2020b;Rogosnitzky et al, 2020).…”

Section: Sildenafilmentioning

confidence: 99%

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives

et al. 2020

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic represents an unprecedented challenge for the researchers to offer safe, tolerable, and effective treatment strategies for its causative agent known as SARS-CoV-2. With the rapid evolution of the pandemic, even the off-label use of existing drugs has been restricted by limited availability. Several old antivirals, antimalarial, and biological drugs are being reconsidered as possible therapies. The effectiveness of the controversial treatment options for COVID-19 such as nonsteroidal antiinflammatory drugs, angiotensin 2 conversion enzyme inhibitors and selective angiotensin receptor blockers was also discussed. A systemic search in the PubMed, Science Direct, LitCovid, Chinese Clinical Trial Registry, and ClinicalTrials.gov data bases was conducted using the keywords "coronavirus drug therapy," passive immunotherapy for COVID-19', "convalescent plasma therapy," (CPT) "drugs for COVID-19 treatment," "SARS-CoV-2," "COVID-19," "2019-nCoV," "coronavirus immunology," "microbiology," "virology," and individual drug names. Systematic reviews, case presentations and very recent clinical guidelines were included. This narrative review summarizes the available information on possible therapies for COVID-19, providing recent data to health professionals.

show abstract

Current Concepts on the Reno-Protective Effects of Phosphodiesterase 5 Inhibitors in Acute Kidney Injury: Systematic Search and Review

Cited by 35 publications

References 121 publications

Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches

Contrast-induced nephropathy and oxidative stress: mechanistic insights for better interventional approaches

Clusterin as a New Marker of Kidney Injury in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation—A Pilot Study

Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives

Contact Info

Product

Resources

About